Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

BUY
$31.23 - $42.99 $189,378 - $260,691
6,064 New
6,064 $204,000
Q1 2022

May 10, 2022

SELL
$17.64 - $39.57 $146,800 - $329,301
-8,322 Closed
0 $0
Q4 2021

Feb 08, 2022

SELL
$34.2 - $47.56 $239 - $332
-7 Reduced 0.08%
8,322 $308,000
Q3 2021

Nov 12, 2021

SELL
$27.88 - $58.25 $52,386 - $109,451
-1,879 Reduced 18.41%
8,329 $398,000
Q2 2021

Aug 13, 2021

BUY
$25.79 - $42.11 $32,392 - $52,890
1,256 Added 14.03%
10,208 $345,000
Q1 2021

May 14, 2021

BUY
$38.75 - $86.92 $11,470 - $25,728
296 Added 3.42%
8,952 $370,000
Q4 2020

Feb 09, 2021

BUY
$34.61 - $123.66 $299,584 - $1.07 Million
8,656 New
8,656 $375,000

Others Institutions Holding ARCT

About Arcturus Therapeutics Holdings Inc.


  • Ticker ARCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,576,400
  • Market Cap $635M
  • Description
  • Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...
More about ARCT
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.